$13.28
1.14%
Nasdaq, Apr 21, 08:49 pm CET
ISIN
US92790C1045
Symbol
VRDN
Sector
Industry

Viridian Therapeutics Inc Stock price

$13.13
-2.91 18.14% 1M
-11.13 45.88% 6M
-6.04 31.51% YTD
-1.95 12.93% 1Y
-3.81 22.49% 3Y
+5.04 62.31% 5Y
-450.37 97.17% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
+0.48 3.79%
ISIN
US92790C1045
Symbol
VRDN
Sector
Industry

Key metrics

Market capitalization $1.07b
Enterprise Value $564.31m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1,881.03
P/S ratio (TTM) P/S ratio 3,566.33
P/B ratio (TTM) P/B ratio 2.20
Revenue growth (TTM) Revenue growth -3.82%
Revenue (TTM) Revenue $300.00k
EBIT (operating result TTM) EBIT $-299.04m
Free Cash Flow (TTM) Free Cash Flow $-232.83m
Cash position $717.58m
EPS (TTM) EPS $-3.77
P/E forward negative
P/S forward 6,674.94
EV/Sales forward 3,520.64
Short interest 14.11%
Show more

Is Viridian Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Viridian Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Viridian Therapeutics Inc forecast:

15x Buy
88%
2x Hold
12%

Analyst Opinions

17 Analysts have issued a Viridian Therapeutics Inc forecast:

Buy
88%
Hold
12%

Financial data from Viridian Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
0.30 0.30
3% 3%
100%
- Direct Costs 1.34 1.34
2% 2%
447%
-1.04 -1.04
3% 3%
-347%
- Selling and Administrative Expenses 59 59
36% 36%
19,680%
- Research and Development Expense 238 238
49% 49%
79,203%
-298 -298
18% 18%
-99,233%
- Depreciation and Amortization 1.34 1.34
2% 2%
447%
EBIT (Operating Income) EBIT -299 -299
18% 18%
-99,679%
Net Profit -255 -255
7% 7%
-84,957%

In millions USD.

Don't miss a Thing! We will send you all news about Viridian Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Viridian Therapeutics Inc Stock News

Neutral
Business Wire
14 days ago
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Jeff Ajer to its Board of Directors. Mr. Ajer has more than 25 years of experience driving commercialization for rare diseases and specialty medicines, in...
Neutral
Business Wire
about one month ago
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the company's Board of Directors approved the grant of non-qualified ...
Positive
Seeking Alpha
about 2 months ago
Viridian Therapeutics' VRDN-001 shows promising data in treating Thyroid Eye Disease (TED), with strong proptosis and diplopia resolution rates, rivaling Amgen's Tepezza. Positive results from Thrive and Thrive-2 trials bolster confidence, with VRDN-001 demonstrating rapid response and consistent efficacy in both active and chronic TED. Financially stable with a cash runway into 2027, Viridian ...
More Viridian Therapeutics Inc News

Company Profile

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma; and remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Boulder, CO.

Head office United States
CEO Stephen Mahoney
Employees 143
Founded 2006
Website www.viridiantherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today